KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,508 | +17.3% | 30,790 | +9.6% | 0.01% | +16.7% |
| Q2 2023 | $252,882 | +14.5% | 28,098 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $220,850 | -9.9% | 28,098 | +100.2% | 0.01% | -28.6% |
| Q3 2021 | $245,000 | -39.4% | 14,036 | -16.7% | 0.01% | -46.2% |
| Q2 2021 | $404,000 | -52.2% | 16,856 | -48.7% | 0.01% | -59.4% |
| Q1 2021 | $845,000 | -60.8% | 32,875 | -71.0% | 0.03% | -60.0% |
| Q4 2020 | $2,156,000 | +29.9% | 113,533 | -13.9% | 0.08% | -20.0% |
| Q3 2020 | $1,660,000 | +9.9% | 131,822 | +5.5% | 0.10% | -2.9% |
| Q2 2020 | $1,511,000 | +82.0% | 124,902 | +15.1% | 0.10% | +49.3% |
| Q1 2020 | $830,000 | +6.5% | 108,492 | +148.0% | 0.07% | +1.5% |
| Q4 2019 | $779,000 | +125.1% | 43,749 | +46.7% | 0.07% | +112.5% |
| Q3 2019 | $346,000 | +137.0% | 29,825 | +37.7% | 0.03% | +33.3% |
| Q3 2017 | $146,000 | -8.2% | 21,665 | 0.0% | 0.02% | -27.3% |
| Q2 2017 | $159,000 | -5.9% | 21,665 | 0.0% | 0.03% | +6.5% |
| Q1 2017 | $169,000 | +45.7% | 21,665 | +32.5% | 0.03% | +19.2% |
| Q4 2016 | $116,000 | – | 16,346 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |